(Reuters) - An independent nonprofit organization that evaluates clinical and cost effectiveness of new medicines found the price of GlaxoSmithKline's new drug for severe asthma should be as much as 76 percent lower to justify its value, according to the group's latest draft report.
http://ift.tt/xePdMM
from Reuters: Health News
via animenewspro
Aucun commentaire:
Enregistrer un commentaire